Current News

06/19/13: Raptor's PROCYSBI™ Now Commercially Available in the U.S. for Nephropathic Cystinosis Patients

06/12/13: Raptor Pharmaceutical to Present at Upcoming Investor Conference

05/08/13: Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial Results

Raptor’s mission is to develop and commercialize life-altering therapeutics that treat debilitating and often fatal diseases.

The Company anticipates receiving a determination from the EMA regarding its PROCYSBI™ marketing application in the European Union in the second half of 2013.